What changed: Locally advanced cervical cancer
Every dated change on the records linked to Locally advanced cervical cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result3Milestone6This record1
September 2026 · 1
2024 · 1
2023 · 4
- 2023Trial resultINTERLACEINTERLACE reported
5-year OS 80% vs 72% (HR 0.
- 2023Trial resultKEYNOTE-A18 / ENGOT-cx11 / GOG-3047KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 reported
PFS HR 0.
- 2023MilestoneINTERLACEINTERLACE: induction carboplatin-paclitaxel improves five-year survival from 72 to 80 percent
A milestone in how this cancer is treated.
- 2023MilestoneKEYNOTE-A18 / ENGOT-cx11 / GOG-3047KEYNOTE-A18: pembrolizumab with chemoradiation improves progression-free and overall survival
A milestone in how this cancer is treated.
2021 · 3
- 2021Trial resultOUTBACK / ANZGOG 0902 / GOG-0274OUTBACK / ANZGOG 0902 / GOG-0274 reported
5-year OS 72% vs 71%; no benefit.
- 2021MilestoneBrachytherapyEMBRACE-I: MRI-guided adaptive brachytherapy gives local control above ninety percent
A milestone in how this cancer is treated.
- 2021MilestoneOUTBACK / ANZGOG 0902 / GOG-0274OUTBACK: adjuvant chemotherapy after chemoradiation gives no benefit
A milestone in how this cancer is treated.